Dexcom Archives - Page 13 of 14 - Medical Design Sourcing

Dexcom Q4 earnings miss by a penny — but revenue up 23%

Dexcom (NSDQ:DXCM) this evening reported mixed Q4 2020 results and reiterated a fiscal year 2021 revenue guidance that is slightly below Wall Street projections.

The San Diego–based continuous glucose monitor company reported profits of $355.2 million, or $3.48 per share, on sales of $568.9 million for the three months ended Dec. 31, 2020, nearly quadrupling the bottom line on 23% sales growth compared with Q4 2019.

Adjusted to exclude one-time items, earnings per share were 91¢, a penny behind The Street, where analysts were looking for EPS of 92¢ on sales of $552.88 million.

Get the full story on our sister site Drug Delivery Business News.

Looking back at two decades of CGM advances

The Freestyle Libre 2 from Abbott

Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history.

Attempts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose testing wasn’t commercialized until 1908, establishing a foundation for diabetes care.

Elkhart, Ind.-based Ames Company refined the process in 1945 with the introduction of Clinitest reagent tablets, which are still commercially available, albeit from Bayer (ETR:BAYN). The company would introduce the first blood glucose test strip in 1965. The Dextrostix-branded strips were intended for use in doctors’ offices.

Get the full story on our sister site, Drug Delivery Business News.

DTW Podcast: CEO Johnson on entrepreneurship, upcoming MedtechColor Pitch Contest; Krum handicaps medtech Q4

In this episode of the DeviceTalks Weekly Podcast, Angelique Johnson, CEO of MEMstim, shares her “accidental entrepreneur” story and how it has enabled her the help others pursuing the same dream.

Also, Johnson, co-founder of MedtechColor, an organization seeking to further the advancement of people of color in the medical device industry, details the group’s goals and invites entrepreneurs of color to apply for the group’s Pitch Contest.

The deadline is Feb. 5. Go to medtechcolor.org for more information.

Truist Securities Managing Director Kaila Krum answers questions about medtech’s Q4 performance, diving deeper on Stryker and other companies.

Krum also shares details on a survey conducted by the research team that sought to answer the question – when will hospitals start seeing elective patients again.

Pharma Editor Brian Buntz returns to tell his story of his 10-days wearing a continuous glucose monitor from Dexcom. Buntz wrote …

How CGMs can inspire lifestyle changes

Dexcom G6 transmitter

As an early adopter of fitness trackers such as the FitBit, I’ve long appreciated the power of health data. But my recent experience with a continuous glucose monitor (CGM) has done far more to inspire me to look after my health — even as a nondiabetic.

I had heard about the potential of such technology before from the cardiologist Dr. Eric Topol, who serves on the board of Dexcom (NASDAQ:DXCM), and the entrepreneur Tim Ferriss, who has discussed using the technology as a non-diabetic to optimize weight loss and muscle gain.

But I have only recently had the chance to evaluate CGM as part of Dexcom’s “Hello Dexcom” sample program that enables patients to try out the company’s G6 CGM at no cost. The goal of the program is to increase awareness among healthcare providers and consumers.

Get the full story from our sister site, Drug Delivery Business.

How CGMs can inspire lifestyle changes

Dexcom G6 transmitter

As an early adopter of fitness trackers such as the FitBit, I’ve long appreciated the power of health data. But my recent experience with a continuous glucose monitor (CGM) has done far more to inspire me to look after my health — even as a nondiabetic.

I had heard about the potential of such technology before from the cardiologist Dr. Eric Topol, who serves on the board of Dexcom (NASDAQ:DXCM), and the entrepreneur Tim Ferriss, who has discussed using the technology as a non-diabetic to optimize weight loss and muscle gain.

But I have only recently had the chance to evaluate CGM as part of Dexcom’s “Hello Dexcom” sample program that enables patients to try out the company’s G6 CGM at no cost. The goal of the program is to increase awareness among healthcare providers and consumers.

Get the full story from our sister site, Drug Delivery Business.

How CGMs can inspire lifestyle changes

G6 from Dexcom

As an early adopter of fitness trackers such as the FitBit, I’ve long appreciated the power of health data. But my recent experience with a continuous glucose monitor (CGM) has done far more to inspire me to look after my health — even as a nondiabetic.

I had heard about the potential of such technology before from the cardiologist Dr. Eric Topol, who serves on the board of Dexcom (NASDAQ:DXCM), and the entrepreneur Tim Ferriss, who has discussed using the technology as a non-diabetic to optimize weight loss and muscle gain.

But I have only recently had the chance to evaluate CGM as part of Dexcom’s “Hello Dexcom” sample program that enables patients to try out the company’s G6 CGM at no cost. The goal of the program is to increase awareness among healthcare providers and consumers.

The G6 device, pictured above, provides blood glucose readings every 5 minutes for 10 days via a smartphone app or dedicated receiver.

Brian Buntz

Mode…

How continuous glucose monitors have transformed the diabetes landscape

G6 applicator from Dexcom

Continuous glucose monitors (CGMs) are among the most potent diabetes management tools to emerge in recent decades.

FDA approved the first professional CGM in 1999, and the technology has evolved swiftly since then. Current models beam data via Bluetooth to smartphones (plus the Apple Watch) and the cloud, enabling patients to explore their blood glucose readings in an app or via downloadable PDFs.

“Decades ago, we were still checking urine sugars,” said Dr. Egils Bogdanovics, a Connecticut-based endocrinologist. “In the early 1980s, fingerstick blood glucose monitors came out. That was a big deal — a revolution in diabetes,” Bogdanovics recalled.

Get the full story from our sister publication, Drug Delivery Business.

These medtech stocks performed the best in 2020

(From Ishant Mishra on Unsplash)

While 2020 did not go as planned for anyone, with the twists and turns came opportunities for medtech companies to power forward.

Innovations came both as a result of the COVID-19 pandemic and perhaps in spite of the challenges brought on by the virus, highlighted by the increased efforts to produce vaccines and testing while pivoting to artificial-intelligence-based and remote care.

Companies like Moderna arose from nowhere, climbing from a share price of $19.52 to $104.47 over the course of the year as it established itself as a frontronner in the race to get a COVID-19 vaccine to the public, eventually becoming the second vaccine authorized in the U.S.

MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — has hit new heights over the course of 2020, indicating the upward trajectory of the industry. Over the course of the year, the index grew from a total of $86.8…

These medtech stocks performed the best in 2020

(From Ishant Mishra on Unsplash)

While 2020 did not go as planned for anyone, with the twists and turns came opportunities for medtech companies to power forward.

Innovations came both as a result of the COVID-19 pandemic and perhaps in spite of the challenges brought on by the virus, highlighted by the increased efforts to produce vaccines and testing while pivoting to artificial-intelligence-based and remote care.

Companies like Moderna arose from nowhere, climbing from a share price of $19.52 to $104.47 over the course of the year as it established itself as a frontronner in the race to get a COVID-19 vaccine to the public, eventually becoming the second vaccine authorized in the U.S.

MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — has hit new heights over the course of 2020, indicating the upward trajectory of the industry. Ove…

MedTech 100 roundup: Industry hits another mid-pandemic high

Despite a minor regression week-over-week, the medtech industry’s stocks hit another milestone as the COVID-19 rebound remains in progress.

MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.01 points at the end of last week (July 31). Overall, medtech stocks saw a -0.3% increase from the 89.29-point total at the same time a week prior (July 24).

On July 30, the index reached 90.37 points, marking its highest point since that pre-pandemic high, with the previous mid-pandemic high (90.11) coming last week.

The most recent high mark represents just a -2.1% dip from the Feb. 19 high point of 92.32, marking the smallest margin of decline over the past five months.

Meanwhile, the S&P 500 Index saw a 1.7% increase from July 24 to July 31, and the Dow Jones Index posted a -0.2% drop over the same period of time.

Medtech’s lowest point during the COVID-19 pandemic remains at …

The top 5 MassDevice stories of the week — July 31, 2020

The past week has seen a slew of Q2 earnings reports from medical device companies — and the picture overall hasn’t been pretty amid the COVID-19 pandemic.

Still, medtech CEOs during their earnings calls said they’re starting to see some signs of hospital procedures recovering a bit even as the southern U.S. deals with a coronavirus wave. Some of the top MassDevice stories this week actually involved companies providing more solutions to improve management of the pandemic.

Want to hear more about the week’s top news? Executive editor Chris Newmarker and Tom Salemi will discuss during our DeviceTalks Weekly podcast. Without further ado, here’s this week’s MassDevice Top Five:

5. A few bright spots amid the COVID-19 financial toll

Dexcom (NSDQ:DXCM) proved to be one of the few bright spots among medtech Q2 earnings reports, blowing away the Wall Street consensus forecast as it successfully pivoted to making its continuous glucose monitors avail…

Dexcom up after hours on Street-beating Q2

Dexcom (NSDQ:DXCM) shares ticked up after hours today on second-quarter results that blew away the consensus forecast.

The San Diego-based continuous glucose monitoring technology developer posted profits of $46.3 million, or 48¢ per share, on sales of $451.8 million for the three months ended June 30, 2020, for a massive bottom-line gain after losses of $10.5 million this time last year on sales growth of 34.3%.

Adjusted to exclude one-time items, earnings per share were 79¢, 44¢ ahead of Wall Street, where analysts were looking for sales of $415.7 million.

During the ongoing COVID-19 pandemic, the company made its CGM systems available to U.S. hospitals and healthcare facilities to assist frontline workers as it adjusted to doing business during the crisis.

“Our growth in the second quarter reflects the commitment of the Dexcom teams to rapidly adjust during the COVID-19 pandemic and ensure service to our customers and our communities,” Dexcom c…